A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

Table 1 MPIs of the HIV-1 Envs to MVC, VVC and TAK-779

Env	MVC				VVC				TAK-779
	MPI	SEM	95% CI	Resistance phenotype	MPI	SEM	95% CI	Resistance phenotype	MPI	SEM	95% CI	Resistance phenotype
17-Sens	99.7	2.1	99.5-103.9	Sensitive	100.5	2.0	96.2-104.7	Sensitive	99.2	2.6	93.7-104.7	Sensitive
17-Res	91.4	1.3	88.7-94.1	Weakly Resistant	98.3	1.9	94.4-102.2	Sensitive	97.2	5.4	85.9-108.5	Sensitive
24-Sens	100.1	1.5	97.1-103.1	Sensitive	99.4	2.0	95.2-103.6	Sensitive	97.5	1.6	94.2-100.7	Sensitive
24-Res	12.5	2.5	7.3-17.6	Strongly Resistant	91.4	2.2	86.9-96.0	Weakly Cross-resistant	94.7	2.3	89.9-99.5	Weakly Cross-resistant

MPIs were determined in NP2-CD4/CCR5 cells, and are calculated from 3 (VVC, TAK-779) or 5 (MVC) independent experiments.
MPI, maximal percent inhibition; SEM, standard error of the mean; CI, confidence interval; MVC, maraviroc; VVC, vicriviroc.

ISSN: 1742-4690